Clinical Trial
Study Details
Status
RECRUITING
Study ID #
NCT06096675
Study Start
Primary Completion
Study Completion
Enrollment
50
Study Type
Interventional
Phase
N/A
Interventions
• Cardiac Rehabilitation

Intervention group will have baseline 6-minute walk test and cardiopulmonary exercise test (CPET) testing followed by supervised cardiac rehabilitation program including planned 3 one hour sessions a week for a total of 12 weeks (planned 36 sessions). A post intervention 6-minute walk test and CPET test will be performed within 2 weeks of completion of the 12 week program.

Primary Outcomes
Measure
Number of participants that complete at least 75% of prescribed cardiac rehab sessions
Description

Feasibility of cardiac rehab as measured by number of participants that complete at least 75% of prescribed cardiac rehab sessions.

Timeframe
Week 12
Secondary Outcomes
Measure
Change in cardiorespiratory fitness - maximal VO2 rates
Description

Change in cardiorespiratory fitness as assessed by maximal (max) rate (V) of oxygen (O₂) your body is able to use during exercise VO2 (ml/kg/min ) on cardiopulmonary exercise test (CPET).

Vo2 Max scores can vary based on a number of factors in addition to fitness, such as your gender, age and genetics, but a vo2 max measurement for an average person in their mid 30s to mid 40s is likely to be around: Women - 31 ml oxygen/kg of body weight/minute. Men - 42 ml oxygen/kg of body weight/minute.

Timeframe
Week 12
Measure
Change in cardiorespiratory fitness - Ventilatory Efficiency (VE/VCO2) rates
Description

Ventilatory equivalent for carbon dioxide ( ˙VE/ ˙VCO2) identifies the second ventilatory threshold, namely, the point in time when ventilatory drive starts increasing relative to ˙VCO2 (i.e., when hyperventilation occurs).

Timeframe
Week 12
Measure
Change in cardiorespiratory fitness - quality of life (KCCQ) Cardiomyopathy Questionnaire (Kansas City) scores
Description

KCCQ scores are scaled from 0 to 100 and frequently summarized in 25-point ranges, where scores represent health status as follows: 0 to 24: very poor to poor; 25 to 49: poor to fair; 50 to 74: fair to good; and 75 to 100: good to excellent.

Timeframe
Week 12
Measure
Change in cardiorespiratory fitness - chronotropic incompetence scores
Description

the inability of the heart to increase its rate commensurate with increased activity or demand, is common in patients with cardiovascular disease, produces exercise intolerance which impairs quality-of-life - chronotropic incompetence is usually defined as failure to achieve a chronotropic index of 0.8 or higher (i.e., falling below 97.5 percent of healthy adults).

Timeframe
Week 12
Measure
Change in cardiorespiratory fitness - 6-minute walk test distance
Description

In healthy subjects, the 6-min walk distance (6MWD) ranges from 400 to 700 m, the main predictor variables being gender, age and height.

Timeframe
Week 12
Summary

Exercise training in patients with heart failure and preserved ejection fraction (HFpEF) has been associated with an improvement in cardiorespiratory fitness and quality of life.

Description

The Atrium Health cardiac rehabilitation program delivers a comprehensive approach to improve cardiac performance including supervised exercise programs and has the ideal infrastructure to offer cardio-oncology rehabilitation (CORE) to all our cancer patients in the future. Currently neither CORE nor cardiac rehabilitation for HFpEF are covered by insurance, and hence the targeting of a higher risk cancer and non-cancer population of cardiac amyloidosis patients to objectively measure the benefits of a supervised exercise program ultimately to expand eligibility to all cancer patients and shape the treatment and payor landscape in the future.

Conditions
Cardiac Amyloidosis
Study Contact
Name
Dana B Amaro, RN
Role
Contact
Phone
704-355-4692
Email
Dana.Amaro@atriumhealth.org
Locations
Facility

Sanger Heart and Vascular Institute
Charlotte, NC 28204
United States

Contacts
Study Contact
Name
Jai Singh, MD
Role
Principal Investigator
Eligibility Criteria

Inclusion Criteria:

* Age \> 18
* New York Heart Association (NYHA) Class I-III Heart Failure
* Able to Exercise
* On stable treatment for their cardiac amyloidosis or under active surveillance
* Life expectancy of at least 6 months
* Ability to understand and the willingness to sign a written informed consent document in English, and the willingness/ability to comply with the protocol activities
* Participant must be able and willing to follow the cardiac rehabilitation activities

Exclusion Criteria:

* Inability to provide informed consent
* Inability to commit to in-person supervised exercise sessions for three one-hour sessions a week for 12 weeks
* NYHA Class IV Heart Failure
* Pulmonary disease requiring home oxygen
* Gait instability or history of prior falls
* In the opinion of the Principal Investigator, have a clinically significant comorbid disease that is likely to affect the ability of the patient to complete the trial, interfere with their ability with measurement of self-reported outcomes.

Eligibility Minimum Age
18 Years
Sexes Eligible for Study
ALL
Eligibility Std Ages
Adult
Older Adult